Seeking Alpha

Geron could get lift from Sanofi's myelofibrosis troubles

  • Shares of Geron (GERN) are up 1.5% before the bell.
  • Although premarket volume is low, the stock could get a boost during the regular session from news that Sanofi has suspended studies of fedratinib.
  • For more on myelofibrosis, see here.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|